European Urology Oncology

Slides:



Advertisements
Similar presentations
Volume 60, Issue 5, Pages (November 2011)
Advertisements

Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated  Michael D. Chuong,
Judith Bosschieter, André N. Vis, Henk G. van der Poel, Luc M
Fred Saad  European Urology Supplements 
European Urology Oncology
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
European Urology Oncology
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Volume 64, Issue 3, Pages (September 2013)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 66, Issue 2, Pages (August 2014)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
European Urology Oncology
Volume 65, Issue 4, Pages (April 2014)
Volume 69, Issue 4, Pages (April 2016)
European Urology Oncology
European Urology Oncology
Laurent Boccon-Gibod  European Urology Supplements 
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
Tillmann Loch, Pat Fox Fulgham  European Urology 
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma  Sergio Bracarda, Alain Ravaud, Marino.
Role of Checkpoint Inhibition in Localized Bladder Cancer
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography  Andrew.
European Urology Oncology
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients Before and After Cytotoxic Chemotherapy or Targeted Therapy 
Atul B. Shinagare, MD, Stuart G. Silverman, MD, Esteban F
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
European Urology Oncology
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Bernard Escudier  European Urology Supplements 
European Urology Oncology
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
European Urology Oncology
European Urology Oncology
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder  Devin N. Patel, Michael Luu, Zachary.
European Urology Oncology
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
European Urology Oncology
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
The Cost to Medicare of Bladder Cancer Care
Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer 
Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report 
European Urology Oncology
European Urology Oncology
PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.
European Urology Oncology
European Urology Oncology
Joaquim Bellmunt  European Urology Supplements 
High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine.
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer  Elena Bolzacchini, MD,
European Urology Oncology
European Urology Oncology
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
European Urology Oncology
(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
European Urology Oncology
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
European Urology Oncology
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.
Maximilian Burger, Ashish M. Kamat, David McConkey 
How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?  Shahrokh Shariat, Paolo Gontero, James.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.
Presentation transcript:

European Urology Oncology Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors  Francesco Alessandrino, Rahul Gujrathi, Amin H. Nassar, Arwa Alzaghal, Arvind Ravi, Bradley McGregor, Guru Sonpavde, Atul B. Shinagare  European Urology Oncology  DOI: 10.1016/j.euo.2019.02.002 Copyright © 2019 Terms and Conditions

Fig. 1 Localization of lesions analyzed at baseline and first follow-up CT. CT=computed tomography. European Urology Oncology DOI: (10.1016/j.euo.2019.02.002) Copyright © 2019 Terms and Conditions

Fig. 2 Region of interest contouring and texture analysis evaluation on first follow-up CT. Contrast-enhanced CT scans of the abdomen show contoured nodal lesions (A) in a patient with progression-free survival (PFS) <12mo and (B) in a patient with PFS >12mo. (C) Histogram analysis of the two lesions shows different shapes of the histogram and higher values of the lesion of patient A (blue line), reflecting higher mean and higher entropy. CT=computed tomography. European Urology Oncology DOI: (10.1016/j.euo.2019.02.002) Copyright © 2019 Terms and Conditions